Abtastung

Patent europeic · EP2573563 · En vigur

Inscripziun en il register

Numer da publicaziun
EP2573563
Numer da la dumonda
EP12192130
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
19-12-2008
Publitgà
27-03-2013
Concedì
25-12-2024
La protecziun finescha il pli tard
18-12-2028
Proxima taxa annuala scadenta
31-12-2026
Classas IPC
G01N 33/566 (2006.01)
C07K 14/705 (2006.01)
C12N 15/10 (2006.01)
G01N 33/543 (2006.01)
Prioritad
GB 0724860 20.12.2007
Derivà da
EP08865061
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-01-2026

    Midada

    Published in Swissreg on 01.01.2026

  2. 05-11-2025

    Midada

    Published in Swissreg on 05.11.2025

  3. 27-12-2024

    Represchentant inscrit

    Representative
    Bovard SA, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 27.12.2024

  4. 25-12-2024

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 25.12.2024

Partidas

Possessur

Nxera Pharma UK Limited

Granta Park Great Abington, Cambridge, Cambridgeshire CB21 6DG, GB

Represchentant

Bovard AG

Bovard SA

Optingenstrasse 16, 3013 Bern

Inventur

Weir, Malcolm Peter

Cambridge CB21 6DG, GB

Marshall, Fiona Hamilton

Cambridge CB21 6DG, GB

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.